Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.51 |
| ▸ | KLF10 | Q13118 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 4/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.38 |
| ▸ | VDR | P11473 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.37 |
| ▸ | RXRG | P48443 | 1/20 | 0.37 |
| ▸ | SHBG | P04278 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5112247 | 0.86 | DAO (0.46) | S1PR1KLF10CYP3A4CYP2D6IDO1 | |
| SCHEMBL7329037 | 0.85 | S1PR1 (0.47) | S1PR1RXRARXRBRXRGKIF11 | |
| SCHEMBL2111621 | 0.84 | IDO1 (0.40) | S1PR1CYP3A4CYP2D6IDO1HTR2A | |
| SCHEMBL10211670 | 0.82 | KLF10 (0.50) | S1PR1KLF10CYP2D6VDRSHBG | |
| SCHEMBL10268650 | 0.82 | KIF11 (0.46) | S1PR1CYP3A4CYP2D6IDO1HTR2A | |
| SCHEMBL13052416 | 0.82 | IDO1 (0.41) | S1PR1CYP3A4CYP2D6IDO1HTR2A | |
| SCHEMBL1014987 | 0.81 | KLF10 (0.44) | KLF10CYP3A4CYP2D6IDO1PDE2A | |
| SCHEMBL31085526 | 0.81 | KLF10 (0.44) | KLF10CYP3A4CYP2D6IDO1PDE2A | |
| SCHEMBL4239916 | 0.80 | IDO1 (0.43) | S1PR1CYP3A4CYP2D6IDO1HTR2A | |
| SCHEMBL14496455 | 0.80 | IDO1 (0.40) | S1PR1CYP3A4CYP2D6IDO1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9890166-B2 | Imidazopyrrolidine derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2018-02-13 | — | — | US | disclosed |
| US-20160108047-A1 | IMIDAZOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2016-04-21 | — | — | US | disclosed |
| EP-2985022-A1 | PROCESS FOR SYNTHESIZING A CETP INHIBITOR | Merck Sharp & Dohme Corp. (US) | 2016-02-17 | — | — | EP | disclosed |
| EP-1983966-B1 | POLYMER FORMULATIONS OF CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2013-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108047-A1 | IMIDAZOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | TPMT, REN, IL5 | S1PR1 867/4885KLF10 3218/4885CYP3A4 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.